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Diazepam, Pentobarbital, and 
Methaqualone Effects on Several 
Behaviors in the Rat and 
Antagonism by Ro 15-1788 
David J. Mokler and Richard H. Rech 
The sedative hypnotics may exert their effects through a number of 
different mechanisms. Diazepam interacts with a specific receptor linked 
to a GABA receptor and a Gl" ionophore (Skolnick and Paul, 1981) and 
enhances the binding affinity of the GABA receptor for its ligand. 
Barbiturates may act at an additional receptor linked to this complex 
(Olsen, 1981). The sites of action of methaqualone have yet to be defined. 
Recently Hunkeler et al. (1981) synthesized a new class of compounds, the 
imidazodiazepines, the prototype being Ro 15-1788. They snowed that 
Ro 15-1788 inhibits H-diazepam binding to brain synaptosomes, reverses 
diazepam-induced protection against metrazol seizures, and alleviates the 
disruption induced by diazepam in a horizontal wire test . Ro 15-1788 does 
not affect the depression induced by phenobarbital, meprobamate or 
ethanol. In a standard conflict paradigm Ro 15-1788 prevents the 
antipunishment effect of diazepam. Ro 15-1788 also antagonizes the 
decrease in rat cerebellar cGMP by diazepam, but not that by barbitur-
ates, ethanol or meprobamate (Mohler et al., 1981), and reverses the 
effects of 3-methylclonazepam in a number of tests in humans (Darragh 
et al., 1981). 
We have investigated the effects of diazepam (DZ), pentobarbital (PB) and 
methaqualone (MQ) alone and in combination with Ro 15-1788 in a novel 
conflict paradigm, conditioned suppression of drinking (CSD), as well as in 
rotarod performance (RR) and motor activity (MA). 
METHODS 
Conditioned Suppression of Drinking (CSD). Female Sprague-Dawley rats 
(150-200 g; Spartan Research Animals, Inc., Haslett, MI) were water -
deprived and trained to drink in 10 min daily sessions from a tube 
protruding through the wall of a 30x56x28 cm plexiglass cage with 
stainless steel floor (Kilts et al., 1981). The driaking tube was attached to 
a calibrated (+0.5 ml) polyethylene tube to monitor fluid consumption. 
When drinking had stabilized, 7-sec tones were presented on a variable 
interval 21 sec schedule. During the last 5 sec of the tone the drinking 
tube and cage floor were electrified (0.03 mA current, C.J. Applegate, 
7.05 
Stimulator Model No. 250, Boulder, CO). Animals were tested six days a 
week at the same time of day. 
Drug treatments were administered every 3-4 days. DZ, PB and MQ were 
administered 10 min and Ro 15-1788 immediately before the session. The 
number of shocks received (punished responding) and the volume of water 
consumed (unpunished responding) on 'drug-days' were divided by these 
measures for the day immediately prior to obtain percent of control 
shocks taken and water consumed, respectively. Changes in water or 
shocks were compared using a multi-factorial ANOVA with least signi-
ficant differences for multiple comparisons; p<0.05 was used as the 
criterion for statistical significance. 
Rotarod Performance (RR). Female Sprague-Dawley rats were trained to 
walk on a rotating rod (RR, 8 rpm). Drugs were tested after animals had 
reached criterion of walking 180 sec for two consecutive trials on two 
consecutive days. Thirty mg/kg DZ, 18 mg/kg PB, 18 mg/kg MQ, or saline 
was administered 15 min before testing and 2.0 mg/kg Ro 15-1788 or 
saline was administered 5 min before testing. Animals were then placed 
on the RR for two consecutive trials; the longest walk was recorded. 
Mean scores for each drug were compared using a one-way ANOVA with 
least significant differences for multiple comparisons (p<0.05 = level of 
significance). 
Motor Activity (MA). Rats used previously in a RR experiment were 
randomly divided into groups regardless of previous drug experience. 
Animals were given 18 mg/kg DZ, 18 mg/kg PB, 18 mg/kg MQ or saline 15 
min before and 2 mg/kg Ro 15-1788 or saline 5 min before being placed 
into motor activity cages. Total counts over 15 minutes were recorded 
using a Stoelting electromagnetic-field counter. Statistical analysis was 
done as described for RR performance. 
Drugs. All drugs were administered i.p. and doses were randomized. Ro 
15-1788 and DZ were gifts from Hoffman-LaRoche, Inc (Nutley, NJ). PB 
sodium was obtained from Sigma Chemical Co. (St. Louis, MO). MQ free 
base was a gift from Wm. H. Rorer, Inc. (Fort Washington, PA). 
Ro 15-1788, DZ and MQ were suspended in 0.5% methylcellulose with two 
drops/10 ml Tween 80. PB sodium was dissolved in distilled water. 
RESULTS 
CSD. Baseline responding consisted of 15.5+0.5 (mean + S.E.M., n = 20) ml 
of water consumed per session and 17+2 (mean + S.E.M., n = 20) shocks 
taken. Both measures were stable across control sessions. Ro 15-1788 
(0.5, 1 or 2 mg/kg), administered alone immediately before the sessions, 
did not alter shock or water scores (zero dose, Fig. 1). DZ (3, 5.6, 10, 18 
and 30 mg/kg) caused a significant increase in punished responding 
(shocks) and, at doses of 18 and 30 mg/kg, caused a decrease in unpunished 
responding (water intake). Ro 15-1788 caused a dose-dependent a t -
tenuation of the effects of DZ on punished responding (F(3, 182) = 21.4). 
At a dose of 0.5 mg/kg, Ro 15-1788 in combination with DZ significantly 
reduced the DZ anticonflict effect, although shocks taken were still above 
baseline with several dose levels. Water intake, reduced by 18 mg/kg DZ 
204 
was significantly different from DZ alone after the drug combination. 
The 1.0 mg/kg dose of Ro 15-1788 nullified the DZ anticonfliet effect for 
all but the 18 mg/kg dose; the DZ-induced decrease in water intake was 
reversed by the combination at the 30 mg/kg DZ dose level but not at 18 
mg/kg DZ. At 2.0 mg/kg, Ro 15-1788 combined with DZ resulted in 
complete attenuation of the DZ anticonfliet effect. The reduction of 
water intake by DZ was not reversed by combination with 2.0 mg/kg Ro 
15-1788. 
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FIG. 1. Effects of diazepam alone and in combination with Ro 15-1788 in 
CSD. 3 = significantly different from control, J^ - significantly 
different from diazepam alone, p<0.05. 
PB (3 to 18 mg/kg) also released punished responding (Fig. 2), being 
maximal at 10 mg/kg. Water intake was significantly decreased at 10 and 
18 mg/kg PB. Combination with 1 or 2 mg/kg Ro 15-1788 did not alter 
the PB effect on the punished component of this behavior. Unpunished 
behavior, however, was significantly potentiated at 18 mg/kg PB by 
combination with 1 or 2 mg/kg Ro 15-1788. MQ (5.6 to 30 mg/kg) also 
caused a release of punished responding, increasing shocks at 10, 18 and 
30 mg/kg (Fig. 3). Unpunished responding was decreased by MQ alone at 
doses of 18 and 30 mg/kg. Combination with Ro 15-1788 (1 mg/kg) did not 
a l te r the effects of MQ on either punished or unpunished responding. 
RR. The results of RR experiments are seen in Fig. 4. Ro 15-1788 (2 
mg/kg) did not alter RR performance. DZ (30 mg/kg) caused a significant 
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disruption of performance; this effect was reversed by Ro 15-1788 com-
bined with 30 mg/kg DZ. In contrast, the disruption by 18 mg/kg PB was 
significantly potentiated by combining with Ro 15-1788. Ro 15-1788 had 
no effect on the disruption of RR walking by 18 mg/kg MQ. 
MA. When compared to saline controls, 2 mg/kg Ro 15-1788 did not have 
an effect by itself on MA measured over 15 min (Fig. 5). DZ (18 mg/kg) 
caused a significant reduction in MA which was almost completely 
reversed by combination with Ro 15-1788. When Ro 15-1788 was given to 
animals receiving either 18 mg/kg PB or 18 mg/kg MQ, their MA was not 
significantly different from that of animals receiving the same dose of PB 
or MQ alone. 
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FIG. 2. Effects of pentobarbital alone and in combination with Ro 15-
1788 in CSD. 3 = significantly different from control, J j = significantly 
different from pentobarbital alone, p<0.05. 
DISCUSSION 
In agreement with Kilts et al. (1981) DZ caused a release of punished 
responding in this conditioned suppression paradigm. Only at higher doses 
(18 and 30 mg/kg) were depressant effects of DZ observed on water 
intake. Since water intake is insignificant during tone periods, it serves 
as a good measure of unpunished responding in the CSD. For example, 5.6 
mg/kg DZ increased punished responding by 1400% without altering the 
level of intake from control (Fig. 1). 
Ro 15-1788 caused a dose-dependent attenuation of the release of 
punished responding elicited by DZ. However, Ro 15-1783 may not 
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FIG. 3. Effects of methaqualone alone and in combination with Ro 15-
1788 in CSD. Q = significantly different from control, p<0.05. 
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FIG. 4. Effects of diazepam, pentobarbital and methaqualone alone (open 
bars) or in eombination with 2.0 mg/kg Ro 15-1788 (filled bars) on rotarod 
performance. * = significantly different from Ro 15-1788 alone, ** = 
significantly different from diazepam alone, * * * = significantly different 
from pentobarbital alone, p<0.05. 
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antagonize some depressant effects of DZ, as evidenced by the inability 
of Ro 15-1788 to reverse in a clear dose-dependent manner the decrease 
in unpunished responding after higher doses of DZ. This is in contrast to 
the findings of Darragh et al. (1981) that Ro 15-1788 is capable of 
reversing the depressant side effects of 3-methylclonazepam in humans. 
It may be that higher doses of Ro 15-1788 would be capable of reversing 
these depressant effects in the CSD. 
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FIG. 5. Effects of diazepam, pentobarbital and methaqualone alone (open 
bars) or in combination with 2.0 mg/kg Ro 15-1788 (filled bars) on motor 
activity. * = significantly different from saline alone, ** = significantly 
different from diazepam alone, p<0.05. 
The apparent lack of effect of Ro 15-1788 on the release of punishment-
suppressed behavior by PB would suggest that the anti-anxiety effects of 
PB are not related to a specific benzodiazepine effect, in agreement with 
other investigators, Barrett and Brady (1982), Brady (this volume), and 
Gorodetzky (this volume). The potentiation by Ro 15-1788 of the depres-
sion in water consumption by higher doses of PB may indicate some 
interaction between these two drugs, however. This has also been 
suggested by Barrett and Brady (1982): Ro 15-1788 potentiated the 
effects of PB in another conflict test. Ro 15-1788 also did not reverse 
the anti-conflict effects of MQ, suggesting that this compound is similar 
to PB in not interacting with the benzodiazepine receptor to produce its 
effects. 
Ro 15-1788 reversed the disruptive effects of DZ on RR and MA, a 
paradox when contrasted with the lack of a clear-cut antagonism by 
Ro 15-1788 of the DZ decrease in the unpunished component of the CSD. 
This suggests that these depressant actions may be working through 
different mechanisms. The potentiation by Ro 15-1788 of PB disruption 
of RR further supports an interaction between these drugs. The current 
study has not ruled out pharmacokinetic interaction. The lack of effect 
of Ro 15-1788 on MQ disruption of RR and MA suggests that this drug 
works by mechanisms that differ from both DZ and PB. 
These experiments indicate that these examples of the sedative-hypnotic 
class of drugs exert their effects through a number of different mecha-
nisms. The anticonflict effects of DZ are clearly mediated through a 
mechanism which is antagonized by Ro 15-1788. This may not be the case 
for the decrease in water intake by DZ in the CSD paradigm. The ant i-
conflict effects of PB and MQ, however, are clearly not mediated through 
a Ro 15-1788-blockable mechanism. The effects of Ro 15-1788 on RR and 
MA depressant actions of DZ, PB and MQ further separate these drugs as 
to mechanisms. Obviously, further study of these interactions is desirable 
to further define differences in the mechanisms of action of these 
sedative-hypnotic agents. 
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